Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - gliclazide, quantity: 60 mg - tablet, modified release - excipient ingredients: sodium acetate; magnesium stearate; lactose monohydrate; silicon dioxide; mannitol; hypromellose - type ii diabetes in association with dietary measures when dietary measures alone are inadequate to control blood glucose.,during controlled clinical trials in patients with type ii diabetes, a modified release formulation of gliclazide (30 mg - 120 mg), taken as a single daily dose, was shown to be effective long term in controlling blood glucose levels, based on monitoring of hba1c.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - gliclazide, quantity: 60 mg - tablet, modified release - excipient ingredients: lactose monohydrate; mannitol; silicon dioxide; hypromellose; magnesium stearate; sodium acetate - type ii diabetes in association with dietary measures when dietary measures alone are inadequate to control blood glucose.,during controlled clinical trials in patients with type ii diabetes, a modified release formulation of gliclazide (30 mg - 120 mg), taken as a single daily dose, was shown to be effective long term in controlling blood glucose levels, based on monitoring of hba1c.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - gliclazide, quantity: 30 mg - tablet, modified release - excipient ingredients: mannitol; hypromellose; sodium acetate; magnesium stearate; lactose monohydrate; silicon dioxide - type ii diabetes in association with dietary measures when dietary measures alone are inadequate to control blood glucose.,during controlled clinical trials in patients with type ii diabetes, a modified release formulation of gliclazide (30 mg - 120 mg), taken as a single daily dose, was shown to be effective long term in controlling blood glucose levels, based on monitoring of hba1c.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - gliclazide, quantity: 60 mg - tablet, modified release - excipient ingredients: magnesium stearate; silicon dioxide; lactose monohydrate; sodium acetate; mannitol; hypromellose - type ii diabetes in association with dietary measures when dietary measures alone are inadequate to control blood glucose.,during controlled clinical trials in patients with type ii diabetes, a modified release formulation of gliclazide (30 mg - 120 mg), taken as a single daily dose, was shown to be effective long term in controlling blood glucose levels, based on monitoring of hba1c.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - gliclazide, quantity: 60 mg - tablet, modified release - excipient ingredients: hypromellose; lactose monohydrate; sodium acetate; mannitol; magnesium stearate; silicon dioxide - type ii diabetes in association with dietary measures when dietary measures alone are inadequate to control blood glucose.,during controlled clinical trials in patients with type ii diabetes, a modified release formulation of gliclazide (30 mg - 120 mg), taken as a single daily dose, was shown to be effective long term in controlling blood glucose levels, based on monitoring of hba1c.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - gliclazide, quantity: 30 mg - tablet, modified release - excipient ingredients: magnesium stearate; hypromellose; mannitol; sodium acetate; silicon dioxide; lactose monohydrate - type ii diabetes in association with dietary measures when dietary measures alone are inadequate to control blood glucose.,during controlled clinical trials in patients with type ii diabetes, a modified release formulation of gliclazide (30 mg - 120 mg), taken as a single daily dose, was shown to be effective long term in controlling blood glucose levels, based on monitoring of hba1c.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - gliclazide, quantity: 30 mg - tablet, modified release - excipient ingredients: magnesium stearate; hypromellose; sodium acetate; silicon dioxide; mannitol; lactose monohydrate - type ii diabetes in association with dietary measures when dietary measures alone are inadequate to control blood glucose.,during controlled clinical trials in patients with type ii diabetes, a modified release formulation of gliclazide (30 mg - 120 mg), taken as a single daily dose, was shown to be effective long term in controlling blood glucose levels, based on monitoring of hba1c.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - gliclazide, quantity: 30 mg - tablet, modified release - excipient ingredients: hypromellose; mannitol; lactose monohydrate; sodium acetate; silicon dioxide; magnesium stearate - type ii diabetes in association with dietary measures when dietary measures alone are inadequate to control blood glucose.,during controlled clinical trials in patients with type ii diabetes, a modified release formulation of gliclazide (30 mg - 120 mg), taken as a single daily dose, was shown to be effective long term in controlling blood glucose levels, based on monitoring of hba1c.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - gliclazide, quantity: 60 mg - tablet, modified release - excipient ingredients: mannitol; magnesium stearate; sodium acetate; silicon dioxide; hypromellose; lactose monohydrate - type ii diabetes in association with dietary measures when dietary measures alone are inadequate to control blood glucose.,during controlled clinical trials in patients with type ii diabetes, a modified release formulation of gliclazide (30 mg - 120 mg), taken as a single daily dose, was shown to be effective long term in controlling blood glucose levels, based on monitoring of hba1c.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - gliclazide, quantity: 30 mg - tablet, modified release - excipient ingredients: hypromellose; magnesium stearate; mannitol; lactose monohydrate; silicon dioxide; sodium acetate - type ii diabetes in association with dietary measures when dietary measures alone are inadequate to control blood glucose.,during controlled clinical trials in patients with type ii diabetes, a modified release formulation of gliclazide (30 mg - 120 mg), taken as a single daily dose, was shown to be effective long term in controlling blood glucose levels, based on monitoring of hba1c.